echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Jiuzhitang FiXase inhibitor is clinically approved by the FDA for the prevention and treatment of venous thrombosis

    Jiuzhitang FiXase inhibitor is clinically approved by the FDA for the prevention and treatment of venous thrombosis

    • Last Update: 2021-07-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On July 19, Jiuzhitang issued an announcement stating that the clinical trial application for the innovative drug YB209 developed by its subsidiary, Youbo Pharmaceutical, was approved by the FDA and was intended to be used for the prevention and treatment of venous thrombosis


    Thromboembolic diseases (such as ischemic stroke, coronary heart disease, deep vein thrombosis, etc.


    In the past four decades, anticoagulant drug research has made remarkable achievements in improving pharmacodynamic properties and oral administration, but it is still in the process of research and development in reducing bleeding tendency


    YB209 is a new class 1 chemical drug.


    Up to now, the project has obtained 17 patent authorization certificates distributed in 8 countries


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.